Impact of Capillary Leak and Hypoalbuminemia on PK/PD of Anidulafungin and Caspofungin in Critically Ill Patients

Launched by UNIVERSITAIRE ZIEKENHUIZEN KU LEUVEN · Aug 2, 2019

Keywords

ClinConnect Summary

This clinical trial is looking at how two antifungal medications, anidulafungin and caspofungin, work in critically ill patients who are receiving treatment in an intensive care unit (ICU). The researchers want to understand how these drugs are absorbed and how effective they are in patients who may have problems like capillary leak syndrome and low levels of a protein called albumin in their blood. This study is important because it could help doctors give the right doses of these medications to improve patient care.

To participate in this study, patients must be 18 years or older, currently being treated with either anidulafungin or caspofungin, and admitted to an ICU. Unfortunately, patients who have a "do not resuscitate" (DNR) order with specific levels (2 or 3) will not be eligible. If someone joins the trial, they can expect to be closely monitored while receiving these medications, which may help researchers learn more about how to treat serious fungal infections in critically ill patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Treatment with anidulafungin or caspofungin
• • Admitted to an ICU ward
• Exclusion Criteria:
• • \< 18 years
• • DNR 2 or 3